-
1 Comment
CSPC Pharmaceutical Group Limited is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
CSPC Pharmaceutical Group Limited's total revenue sank by 0.0% to $6B since the same quarter in the previous year.
Its net income has dropped by 0.0% to $933M since the same quarter in the previous year.
Based on the above factors, CSPC Pharmaceutical Group Limited gets an overall score of 2/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | HK1093012172 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | 8B |
|---|---|
| PE Ratio | 16.88 |
| Target Price | None |
| Dividend Yield | 3.5% |
| Beta | 0.64 |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CVG.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
